Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07176-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Solène Malmon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Pixilib SAS, Toulouse, France. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Tumor Burden, Lymphoma, Image Processing, Computer-Assisted. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This study compared the prognostic value of total metabolic tumor volume (TMTV) in lymphoma measured with the recently proposed SUV4.0 segmentation threshold versus the 41% SUVmax across LYSA trials and its impact on intensity and dissemination PET features. METHODS: A total of 1960 baseline PET/CT scans of Diffuse Large B cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin lymphoma (HL) patients were collected. After a semi-automatic preselection of region of interest, two different segmentation threshold were applied: 41% SUVmax (TMTV41%) and SUV > 4.0 (TMTV4.0). RESULTS: The correlation between TMTV4.0 and TMTV41% was ρ = 0.90 for DLBCL, ρ = 0.65 for FL and ρ = 0.60 for HL. For SUVmax, SUVpeak, Dmax and Dbulk features, a strong correlation was observed with ρ > 0.95 whatever the lymphoma subtypes. The predictability of TMTV was high and comparable for the two methods with superimposable confidence intervals for the three subtypes. At the 90th percentile TMTV value, the predicted 7-year PFS was 51.13% with TMTV4.0 vs. 49.7% with TMTV41% for DLBCL patients, 45.5% vs. 39.8% for FL patients, and 82.6% vs. 80.5% for HL patients. A minority of patients showed a predicted PFS deviation > 10% between the two methods: 2.33% in DLBCL, 6.51% in FL and 1% in HL. CONCLUSION: TMTV measured with the SUV4.0 threshold provides a comparable PFS prediction than the 41%SUVmax method supporting its routine adoption particularly in the diffuse large B cell lymphoma subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pixilib SAS, Toulouse, France.
- Biostatistics Department, LYSARC, Lyon-Sud Hospital, Pierre-Bénite, France.
- APHP, Hôpital Saint-Louis, Hemato-Oncology, Paris, France.
- Université Paris Cité, Paris, France.
- Department of Hematology, Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche Sur les Formes Injectables et les Technologies Associées, Lille, F-59000, France.
- Department of Hematology, CHU Dijon and INSERM UMR1231, Dijon, France.
ORCID-Profile: Anne-Ségolène Cottereau
Zitieren
APA
Malmon, S., Elsensohn, M. H., Thieblemont, C., Morschhauser, F., Casasnovas, O., André, M., Gouill, S. L., Tabaa, Y. A., Durand, P. B., Bailly, C., Edeline, V., Vija, L., Vercellino, L., Ricci, R., Kanoun, S., & Cottereau, A. S. (2025). Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07176-4
Vancouver
Malmon S, Elsensohn MH, Thieblemont C, Morschhauser F, Casasnovas O, André M, et al. Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07176-4
BibTeX
@article{Malmon2025,
author = {Malmon, Solène and Elsensohn, Mad-Helenie and Thieblemont, Catherine and Morschhauser, Franck and Casasnovas, Olivier and André, Marc and Gouill, Steven Le and Tabaa, Yassine Al and Durand, Paul Bland and Bailly, Clement and Edeline, Veronique and Vija, Lavinia and Vercellino, Laetitia and Ricci, Romain and Kanoun, Salim and Cottereau, Anne-Ségolène},
title = {Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07176-4}
}
EUVIMED